NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NYSE · CHE · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Chemed Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Chemed Corporation’s forward annual dividend is $2.80 per share, paid quarterly. The forward yield is 0.52% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Chemed Corporation’s next earnings report is currently expected on Feb 24, 2027, with estimated earnings per share of $7.35. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Chemed Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 | Jul 29, 2025 | $4.27-10.67% vs estimate | $618.80M-1.96% vs estimate |
|---|
| Q1 2025 | Apr 23, 2025 | $5.63+1.44% vs estimate | $646.94M+0.8% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | $6.83+0.74% vs estimate | $639.99M+0.61% vs estimate |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $635.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
$31.85+$0.56 (+1.79%)
Option Care Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.45% below the high.
$13.26+$0.20 (+1.53%)
Aveanna Healthcare Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.86% below the high.
$124.34+$2.16 (+1.77%)
Addus HomeCare Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.92% below the high.
$42.48+$0.32 (+0.76%)
The Pennant Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.14% below the high.
